Role of aldo-keto reductase enzymes in mediating the timing of parturition

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  Byrns, Michael C ^a  

^a ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

Aldo Keto Reductases; Myometrium; Parturition; Placenta; Pregnancy; Prostaglandin metabolism; Steroid metabolism

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; 20 OXOSTEROID; 5BETA DIHYDROPROGESTERONE; ALDO KETO REDUCTASE; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1C1; ALDO KETO REDUCTASE 1C2; ALDO KETO REDUCTASE 1C3; ALDO KETO REDUCTASE 1D1; ANDROSTENEDIONE; ESTRONE; GESTAGEN; INDOMETACIN; LIGAND; MIFEPRISTONE; OXIDOREDUCTASE; OXOSTEROID; OXYTOCIN; PROGESTERONE; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROSTANOID F RECEPTOR; PROSTANOID RECEPTOR; STEROID 5BETA REDUCTASE; STEROID REDUCTASE; UNCLASSIFIED DRUG; UTERUS SPASMOLYTIC AGENT;

ARTICLE; BIRTH; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; LABOR INDUCTION; METABOLITE; NONHUMAN; PREGNANCY; PREMATURE LABOR; PROGESTERONE BLOOD LEVEL; PROGESTERONE METABOLISM; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84866000363     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00092     Document Type: Article

References (62)

1. Amin,Z.,Mason,G. F.,Cavus,I.,Krystal, J. H., Rothman, D. L., and Epperson, C. N. (2006). The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. Pharmacol. Biochem. Behav. 84, 635-643.
2. Andersson, S., Minjarez, D., Yost, N. P., and Word, R. A. (2008). Estrogen and progesterone metabolism in the cervix during pregnancy and parturition. J. Clin. Endocrinol. Metab. 93, 2366-2374.
3. Astle, S., Khan, R. N., and Thornton, S. (2003). The effects of a progesterone metabolite, 5βdihydroprogesterone, on oxytocin receptor binding in human myometrial membranes. BJOG 110, 589-592.
4. Bresson, E., Boucher-Kovalik, S., Chapdelaine, P., Madore, E., Harvey, N., Laberge, P. Y., Leboeuf, M., and Fortier, M. A. (2011). The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J. Clin. Endocrinol. Metab. 96, 210-219.
5. Breuiller-Fouché, M., Leroy, M. J., Dubois, O., Reinaud, P., Chissey, A., Qi, H., Germain, G., Fortier, M. A., and Charpigny, G. (2010). Differential expression of the enzymatic system controlling synthesis, metabolism, and transport of PGF2αin human fetal membranes. Biol. Reprod. 83, 155-162.
6. Brodt-Eppley, J., and Myatt, L. (1999). Prostaglandin receptors in lower segment myometrium during gestation and labor. Obstet. Gynecol. 93, 89-93.
7. Burger, K., Fahrenholz, F., and Gimpl, G. (1999). Non-genomic effects of progesterone on the signaling function of G protein-coupled receptors. FEBS Lett. 464, 25-29.
8. Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., and Penning, T. M. (2010). Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J. Steroid Biochem. Mol. Biol. 118, 177-187.
9. Byrns, M. C., Steckelbroeck, S., and Penning, T. M. (2008). An indomethacin analogue, N-(4chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 517β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem. Pharmacol. 75, 484-493.
10. Charbonneau, A., and Luu-The, V. (2001). Genomic organization of a human 5β-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim. Biophys. Acta 1517, 228-235.
11. Chen, M., Drury, J. E., and Penning, T. M. (2011). Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1). Steroids 76, 484-490.
12. Di Costanzo, L., Drury, J. E., Penning, T. M., and Christianson, D. W. (2008). Crystal structure of human liver Δ4-3-ketosteroid 5β-reductase (AKR1D1) and implications for substrate binding and catalysis. J. Biol. Chem. 283, 16830-16839.
13. Diaz-Zagoya, J. C., Wiest, W. G., and Arias, F. (1979). 20α-Hydroxysteroid oxidoreductase activity and 20αdihydroprogesterone concentration in human placenta before and after parturition. Am. J. Obstet. Gynecol. 133, 673-676.
14. Dong, Y. L., and Yallampalli, C. (2000). Pregnancy and exogenous steroid treatments modulate the expression of relaxant EP2 and contractile FP receptors in the rat uterus. Biol. Reprod. 62, 533-539.
15. Dufort, I., Rheault, P., Huang, X. F., Soucy, P., and Luu-The, V. (1999). Characteristics of a highly labile human type 5 17betahydroxysteroid dehydrogenase. Endocrinology 140, 568-574.
16. Faucher, F., Cantin, L., Luu-The, V., Labrie, F., and Breton, R. (2008). Crystal structures of human Δ4-3ketosteroid 5β-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry 47, 13537-13546.
17. Friel, A. M., O'Reilly, M. W., Sexton, D. J., and Morrison, J. J. (2005). Specific PGF2α receptor (FP) antagonism and human uterine contractility in vitro. BJOG 112, 1034-1042.
18. Goldenberg, R. L., Culhane, J. F., Iams, J. D., and Romero, R. (2008). Epidemiology and causes of preterm birth. Lancet 371, 75-84.
19. Grazzini, E., Guillon, G., Mouillac, B., and Zingg, H. H. (1998). Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392, 509-512.
20. Grundmann, U., Bohn, H., Obermeier, R., and Amann, E. (1990). Cloning and prokaryotic expression of a biologically active human placental aldose reductase. DNA Cell Biol. 9, 149-157.
21. Hevir, N., Vouk, K., Sinkovec, J., Ribič-Pucelj, M., and Rižner, T. L. (2011). Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem. Biol. Interact. 191, 217-226.
22. Hill, M., Cibula, D., Havlíková, H., Kancheva, L., Fait, T., Kancheva, R., Pařízek, A., and Stárka, L. (2007). Circulating levels of pregnenolone isomers during the third trimester of human pregnancy. J. Steroid Biochem. Mol. Biol. 105, 166-175.
23. Hill, M., Pařízek, A., Cibula, D., Kancheva, R., Jirásek, J. E., Jirkovská, M., Velíková, M., Kubátová, J., Klímková, M., Pašková, A., Zižka, Z., Kancheva, L., Kazihnitková, H., Zamrazilová, L., and Stárka, L. (2010). Steroid metabolome in fetal and maternal body fluids in human late pregnancy. J. Steroid Biochem. Mol. Biol. 122, 114-132.
24. Hill, M., Pařízek, A., Kancheva, R., and Jirásek, J. E. (2011). Reduced progesterone metabolites in human late pregnancy. Physiol. Res. 60, 225-241.
25. Hirst, J. J., Yawno, T., Nguyen, P., and Walker, D. W. (2006). Stress in pregnancy activates neurosteroid production in the fetal brain. Neuroendocrinology 84, 264-274.
26. Hoyer, P. B., Marion, S. L., Stine, I., Rueda,B. R.,Hamernik,D. L.,Regan, J. W., and Wise, M. E. (1999). Ovine prostaglandin F2α receptor: steroid influence on steady-state levels of luteal mRNA. Endocrine 10, 105-111.
27. Iams, J. D., Romero, R., Culhane, J. F., and Goldenberg, R. L. (2008). Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 371, 164-175.
28. Jin, Y., Mesaros, A. C., Blair, I. A., and Penning, T. M. (2011). Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldoketo reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5βreductase pathway. Biochem. J. 437, 53-61.
29. Kabututu, Z., Manin, M., Pointud, J. C., Maruyama, T., Nagata, N., Lambert, S., Lefrançois-Martinez, A. M., Martinez, A., and Urade, Y. (2009). Prostaglandin F2α synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. J. Biochem. 145, 161-168.
30. Kawamata, M., Yoshida, M., Sugimoto, Y., Kimura, T., Tonomura, Y., Takayanagi, Y., Yanagisawa, T., and Nishimori, K. (2008). Infusion of oxytocin induces successful delivery in prostanoid FP-receptor-deficient mice. Mol. Cell. Endocrinol. 283, 32-37.
31. Kelly, A. J., Kavanagh, J., and Thomas, J. (2003). Vaginal prostaglandin (PGE2 and PGF2α) for induction of labour at term. Cochrane Database Syst. Rev. 7, CD003101.
32. Kubli-Garfias, C., Medrano-Conde, L., Beyer, C., and Bondani, A. (1979). In vitro inhibition of rat uterine contractility induced by 5α and 5β progestins. Steroids, 34, 609-617.
33. Kulier, R., Kapp, N., Gülmezoglu, A. M., Hofmeyr, G. J., Cheng, L., and Campana, A. (2011). Medical methods for first trimester abortion. Cochrane Database Syst. Rev. 11, CD002855.
34. Lee, R. H., Stanczyk, F. Z., Stolz, A., Ji, Q., Yang, G., and Goodwin, T. M. (2008a). AKR1C1 and SRD5A1 messenger RNA expression at term in the human myometrium and chorioamniotic membranes. Am. J. Perinatol. 25, 577-582.
35. Lee, S. E., Romero, R., Park, I. S., Seong, H. S., Park, C. W., and Yoon, B. H. (2008b). Amniotic fluid prostaglandin concentrations increase before the onset of spontaneous labor at term. J. Matern. Fetal. Neonatal. Med. 21, 89-94.
36. Mackeen, A. D., Seibel-Seamon, J., Grimes-Dennis, J., Baxter, J. K., and Berghella, V. (2011). Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst. Rev. 5, CD007062.
37. Madore, E., Harvey, N., Parent, J., Chapdelaine, P., Arosh, J. A., and Fortier, M. A. (2003). An aldose reductase with 20α-hydroxysteroid dehydrogenase activity is most likely the enzyme responsible for the production of prostaglandin F2αin the bovine endometrium. J. Biol. Chem. 278, 11205-11212.
38. Matsuura, K., Shiraishi, H., Hara, A., Sato, K., Deyashiki, Y., Ninomiya, M., and Sakai, S. (1998). Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J. Biochem. 124, 940-946.
39. McGill, J., and Shetty, A. (2007). Mifepristone and misoprostol in the induction of labor at term. Int. J. Gynaecol. Obstet. 96, 80-84.
40. Mijovic, J. E., Zakar, T., Angelova, J., and Olson, D. M. (1999). Prostaglandin endoperoxide H synthase mRNA expression in the human amnion and decidua during pregnancy and in the amnion at preterm labour. Mol. Hum. Reprod. 5, 182-187.
41. Milewich, L., Gant, N. F., Schwarz, B. E., Chen, G. T., and Macdonald, P. C. (1978). Initiation of human parturition. IX. Progesterone metabolism by placentas of early and late human gestation. Obstet. Gynecol. 51, 278-280.
42. Mitchell, B. F., Mitchell, J. M., Chowdhury, J., Tougas, M., Engelen, S. M., Senff, N., Heijnen, I., Moore, J. T., Goodwin, B., Wong, S., and Davidge, S. (2005). Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? Am. J. Obstet. Gynecol. 192, 1304-1313.
43. Nagata, N., Kusakari, Y., Fukunishi, Y., Inoue, T., and Urade, Y. (2011). Catalytic mechanism of the primary human prostaglandin F2α synthase, aldo-keto reductase 1B1 - prostaglandin D2 synthase activity in the absence of NADP(H). FEBS J. 278, 1288-1298.
44. Nanjidsuren, T., Naidansuren, P., Park, C. W., Park, J. J., Yun, S. J., Sim, B. W., Kang, M. H., Lee, S. R., Chang, K. T., and Min, K. S. (2011). Expression and localization of the 20α-hydroxysteroid dehydrogenase (HSD) enzyme in the reproductive tissues of the cynomolgus monkey Macaca fascicularis. J. Steroid Biochem. Mol. Biol. 127, 337-344.
45. Nishizawa, M., Nakajima, T., Yasuda, K., Kanzaki, H., Sasaguri, Y., Watanabe, K., and Ito, S. (2000). Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldoketo reductase genes. Genes Cells 5, 111-125.
46. Olson, D. M., Zaragoza, D. B., Shallow, M. C., Cook, J. L., Mitchell, B. F., Grigsby, P., and Hirst, J. (2003). Myometrial activation and preterm labour: evidence supporting a role for the prostaglandin F receptor- areview.Placenta 24(Suppl. A), S47-S54.
47. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., Moore, M., Palackal, N., and Ratnam, K. (2000). Human 3αhydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351(Pt 1), 67-77.
48. Putnam, C. D., Brann, D. W., Kolbeck, R. C., and Mahesh, V. (1991). Inhibition of uterine contractility by progesterone and progesterone metabolites: mediation by progesterone and gamma amino butyric acidA receptor systems. Biol. Reprod. 45, 266-272.
49. Reddy, D. S. (2010). Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog. Brain Res. 186, 113-137.
50. Sheehan, P. M. (2006). A possible role for progesterone metabolites in human parturition. Aust. N. Z. J. Obstet. Gynaecol. 46, 159-163.
51. Sheehan, P. M., Rice, G. E., Moses, E. K., and Brennecke, S. P. (2005). 5β-dihydroprogesterone and steroid 5β-reductase decrease in association with human parturition at term. Mol. Hum. Reprod. 11, 495-501.
52. Slater,D.,Dennes,W.,Sawdy,R.,Allport, V., and Bennett, P. (1999). Expression of cyclo-oxygenase types-1 and -2 in human fetal membranes throughout pregnancy. J. Mol. Endocrinol. 22, 125-130.
53. Smith, R. (2007). Parturition. N. Engl. J. Med. 356, 271-283.
54. Smith, W. L., Urade, Y., and Jakobsson, P. J. (2011). Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev. 111, 5821-5865.
55. Srivastava, S. K., Ramana, K. V., and Bhatnagar, A. (2005). Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26, 380-392.
56. Steckelbroeck, S., Jin, Y., Gopishetty, S., Oyesanmi, B., and Penning, T. M. (2004). Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J. Biol. Chem. 279, 10784-10795.
57. Sugimoto, Y., Yamasaki, A., Segi, E., Tsuboi, K., Aze, Y., Nishimura, T., Oida, H., Yoshida, N., Tanaka, T., Katsuyama, M., Hasumoto, K., Murata, T., Hirata, M., Ushikubi, F., Negishi, M., Ichikawa, A., and Narumiya, S. (1997). Failure of parturition in mice lacking the prostaglandin F receptor. Science 277, 681-683.
58. Suzuki-Yamamoto, T., Nishizawa, M., Fukui, M., Okuda-Ashitaka, E., Nakajima, T., Ito, S., and Watanabe, K. (1999). cDNA cloning, expression and characterization of human prostaglandin F synthase. FEBS Lett. 462, 335-340.
59. Thornton, S., Terzidou, V., Clark, A., and Blanks, A. (1999). Progesterone metabolite and spontaneous myometrial contractions in vitro. Lancet 353, 1327-1329.
60. Veliça, P., Davies, N. J., Rocha, P. P., Schrewe, H., Ride, J. P., and Bunce, C. M. (2009). Lack of functional and expression homology between human and mouse aldoketo reductase 1C enzymes: implications for modelling human cancers. Mol. Cancer 8, 121.
61. Watanabe, K. (2011). Recent reports about enzymes related to the synthesis of prostaglandin (PG) F2 (PGF2α and 9α,11β-PGF2). J. Biochem. 150, 593-596.
62. Zakar, T., and Hertelendy, F. (2007). Progesterone withdrawal: key to parturition. Am. J. Obstet. Gynecol. 196, 289-296.